Activins and activin antagonists in hepatocellular carcinoma
Activins and activin antagonists in hepatocellular carcinoma作者机构：Institute of Cancer Research Department of Medicine IMedical University of Vienna Borschkegasse 8aVienna A-1090Austria
出 版 物：《World Journal of Gastroenterology》 (世界胃肠病学杂志（英文版）)
年 卷 期：2008年第14卷第11期
页 面：1699-1709页
核心收录：
学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学]
主 题：Hepatocellular carcinoma Activin Follistatin Transforming growth factor β
摘 要：In many parts of the world hepatocellular carcinoma (HCC)is among the leading causes of cancer-related mortality but the underlying molecular pathology is still insufficiently *** is increasing evidence that activins,which are members of the transforming growth factorβ(TGFβ)superfamily of growth and differentiation factors,could play important roles in liver *** are disulphide-linked homo- or heterodimers formed from four differentβsubunits termedβA,βB,βC,andβE,*** A, the dimer of twoβA subunits,is critically involved in the regulation of cell growth,apoptosis,and tissue architecture in the liver,while the hepatic function of other activins is largely unexplored so *** regulators of activin signals include antagonists in the extracellular space like the binding proteins follistatin and FLRG,and at the cell membrane antagonistic coreceptors like Cripto or ***,in the intracellular space inhibitory Smads can modulate and control activin *** data suggest that deregulation of activin signals contributes to pathologic conditions such as chronic inflammation,fibrosis and development of *** current article reviews the alterations in components of the activin signaling pathway that have been observed in HCC and discusses their potential significance for liver tumorigenesis.
维普期刊数据库